Taking products from zero entry to market leader

Health Vision Enterprise commercialises quality products and grows them into leading brands across China. We unlock value by positioning the brand in ways that match the culture, and capture the needs of the Chinese people. We believe that the positioning of the product is a key determinant of the product’s life cycle and often opt for a blue ocean strategy1 approach to create new markets. With the influx of products into the China market, brand integrity has become very important to the Chinese people. Our emphasis in building trusted brands pays off, especially for those that are first to market. We also facilitate your patent applications in China and take actives steps in protecting your intellectual property.

“To enter China’s highly competitive market place with your pharma product, you need to partner with an experienced marketing company with a distinguished track record who is competent, connected, and transparent. Health Vision Enterprise’s highest values include a passion for excellence, candid communications, and integrity in all transactions. That is why many pharma companies have placed their trust and products with us. Even in this challenging market, we will increase our revenues and market share as we introduce new products into the potentially largest market in the world. Health Vision Enterprise is poised for further rapid growth in the coming ten-year period.” – Zona Yim, Strategic Planning & Development Director, Health Vision Enterprise

1 Kim, W.C., Mauborgne, R. (2005). Blue Ocean Strategy: How to Create Uncontested Market Space and Make the Competition Irrelevant. Boston: Harvard Business School Press.

    • 2

      Aethoxysklerol® is the most widely used sclerosing agent worldwide. The injection provides a low cost, and minimal invasive option to surgery for the effective removal of varicose veins. There are an estimated 119 million varicose vein sufferers in China with many receiving insufficient treatment due to shortage of hospital beds or ineffective treatment options. Aethoxysklerol® will soon be available in China.

      Learn More
    • 1

      Alpha-Lipon 300 Stada® is powerful anti oxidant approved for the treatment of diabetic polyneuropathy. It was launched in China in 2005 as the branded product of alpha-lipoic acid. where we successfully obtained the price reserved for “branded” products in the majority of tender bids. Around 92.4 million adults or 9.7% of the adult population in China suffer from diabetes. Polyneuropathy is the most common complication of diabetes with 60% to 70% of sufferers experiencing mild to severe forms of nervous system damage. Alpha-Lipon® is included on the China National Reimbursement Drug List B and the Zhejiang Essential Drug List. To strengthen sales and marketing activities, we signed a sublicensing agreement with Eisai China Inc. on July 30th 2008 for the promotion of the product. Alpha-Lipon® remains the only imported alpha-lipoic formulation available in China.

      Learn More
    • 7

      Gelomyrtol® Forte is a plant derived formulation for the treatment of acute and chronic sinusitis, and bronchitis. It was launched in China in 1996. The country suffers from high incidence rates of bronchitis and sinusitis as a result of heavy air pollution, and due to the fact that it is home to 25% of the world’s smoking population. With evidence based studies supporting its efficacy in improving the function of mucociliary clearance in the airways, we have created a unique category position for this product in China. As a result, Gelomyrtol® Forte is the most widely prescribed drug in sinusitis treatment in China. It is included on the China National Reimbursement Drug List B and on the Guangdong and Zhejiang Essential Drug List.

      Learn More
    • 6

      Gelomyrtol® Forte Children is a plant derived formulation that works on the mucociliary clearance by removing mucus in both the upper and lower respiratory airways. It was launched in China in 1996. Children with bronchitis often have accompanying rhinitis and otitis media. In all these diseases, the mucociliary clearance is compromised. With a market size of approximately 536 million Renminbi in the hospital sector, Gelomyrtol® Forte Children with its unique mode of action on the mucociliary clearance has an obvious advantage over standard expectorants. It is included on the China National Reimbursement Drug List B and on the Guangdong and Zhejiang Essential Drug List.

      Learn More
    • 4

      Gloria® Med Stockings are manufactured using the most advance technology supported by over one hundred years of family experience. The product is FDA and EU approved with ISO 9001:2000 certification and has been awarded with the “Quality Mark for Medical Compression Hosiery” in Germany. Medical stockings are used for both prevention and treatment of venous disease and had a market value of 1.3 billion Renminbi in China in 2012. Gloria® Med Stockings will soon be launched in China together with Aethoxyskerol® as part of a total solution for varicose vein treatment in hospitals.

      Learn More
    • 9

      Kamistad® is a unique, triple-action formulation in a gel base for the treatment of oral inflammations. It rapidly relieves pain and facilitates healing with an anti-inflammatory and antibacterial effect. It was launched in China in 2007 and has demonstrated good potential in the oral mouth ulcer market that covers both the OTC and hospital sector. There is no generic product in China. It is highly praised by dentists and patients alike.

      Learn More
    • 10

      Nitrolingual® is a fast relieving nitroglycerin formulation for the relief of angina. It is a low alcohol spray formulation that works significantly faster than traditional sublingual tablets. It was launched in China in 1995. Using the United States as a benchmark, by extrapolation it is estimated that there are over 30 million angina suffers in China. Nitrolingual® is included on the China National Reimbursement Drug List A and is the only nitroglycerin spray formulation with United States FDA approval.

      Learn More
    • 11

      Tranilast is the only clinically proven oral therapy indicated for the treatment of keloid and hypertrophic scars where only a few other proven treatment options exist. It can be used together with external scar therapies such as silicone gels for faster results. Considering that China performs an estimated forty million surgical procedures per year1, the opportunities are enormous. Tranilast is a highly researched drug that is also indicated for asthma, allergic rhinitis, and atopic dermatitis. In addition, several studies are now underway for various other indications including the use as an anti-proliferative drug on drug-eluting stents, the treatment of rheumatoid arthritis, and the treatment of cancer. Tranilast will be launched in China in 2015.

      Learn More